Patents by Inventor Stephen M. Kaminsky

Stephen M. Kaminsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APOE GENE THERAPY
    Publication number: 20230044351
    Abstract: A gene therapy vector comprising an expression cassette coding for a mammalian apolipoprotein E that has a residue other than arginine at at least one of positions 112, 136, or 158, but is not a mammalian apolipoprotein E that has R112, R136 and R158 or a mammalian apolipoprotein E that has C112, R136 and C158, or coding for an antibody that binds to APOE4 or disrupts the binding of APOE to heparan sulfate proteoglycans, and methods of using the vector, are provided.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 9, 2023
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Katie M Stiles, Dolan Sondhi
  • GENE THERAPY FOR OXIDATIVE STRESS
    Publication number: 20210381002
    Abstract: Compositions and methods for anti-oxidant therapy are provided.
    Type: Application
    Filed: April 3, 2019
    Publication date: December 9, 2021
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Christiana Salami
  • TREATMENT OF BRAIN CANCERS USING CENTRAL NERVOUS SYSTEM MEDIATED GENE TRANSFER OF MONOCLONAL ANTIBODIES
    Publication number: 20210171656
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Application
    Filed: July 13, 2020
    Publication date: June 10, 2021
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • OXIDATION-RESISTANT AAT GENE THERAPY
    Publication number: 20200102575
    Abstract: A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, for example, Met358 and/or Met351.
    Type: Application
    Filed: March 29, 2018
    Publication date: April 2, 2020
    Inventors: Ronald G. Crystal, Katie Stiles, Meredith Sosulski, Stephen M. Kaminsky, Dolan Sondhi, Bishnu De, Jonathan Rosenberg
  • AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
    Patent number: 10093947
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 9, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson
  • Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
    Patent number: 10004811
    Abstract: The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 26, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Jonathan B. Rosenberg, Bishnu P. De, Martin J. Hicks, Stephen M. Kaminsky
  • Disrupted adenovirus-based vaccine against drugs of abuse
    Patent number: 9682133
    Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.
    Type: Grant
    Filed: March 17, 2011
    Date of Patent: June 20, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky
  • DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION NICOTINE-CONJUGATE VACCINE TO TREAT NICOTINE ADDICTION
    Publication number: 20150297739
    Abstract: The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 22, 2015
    Inventors: Ronald G. Crystal, Jonathan B. Rosenberg, Bishnu P. De, Martin J. Hicks, Stephen M. Kaminsky
  • TREATMENT OF BRAIN CANCERS USING CENTRAL NERVOUS SYSTEM MEDIATED GENE TRANSFER OF MONOCLONAL ANTIBODIES
    Publication number: 20150210771
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Application
    Filed: September 13, 2013
    Publication date: July 30, 2015
    Inventors: Ronald G. CRYSTAL, Stephen M. KAMINSKY, Martin J. HICKS, Vivian TABAR
  • VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS
    Publication number: 20150182638
    Abstract: The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Donald Joseph D'Amico, Julie Boyer, Szilard Kiss
  • AAV-DIRECTED PERSISTENT EXPRESSION OF AN ANTI-NICOTINE ANTIBODY GENE FOR SMOKING CESSATION
    Publication number: 20150056251
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody that binds to nicotine or a nicotine analog, or an antigen-binding fragment thereof. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 26, 2015
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson
  • VIRUS-MEDIATED DELIVERY OF BEVACIZUMAB FOR THERAPEUTIC APPLICATIONS
    Publication number: 20130090375
    Abstract: The invention provides a method of inhibiting ocular neovascularization in a mammal by administering a composition comprising a bevacizumab-encoding adeno-associated virus (AAV) vector directly to the eye of the mammal.
    Type: Application
    Filed: June 29, 2012
    Publication date: April 11, 2013
    Applicant: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Donald Joseph D'Amico, Julie Boyer, Szilard Kiss
  • DISRUPTED ADENOVIRUS-BASED VACCINE AGAINST DRUGS OF ABUSE
    Publication number: 20130011432
    Abstract: The invention is directed to an adenovirus-antigen conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus, as well as a conjugate comprising (a) a disrupted adenovirus with a coat protein and (b) an antigen conjugated to the coat protein of the disrupted adenovirus. The invention also provides a method of inducing an immune response against an antigen in a human using the aforementioned conjugates. The invention further provides an adeno-associated viral vector comprising a nucleic acid sequence which encodes an antibody directed against cocaine.
    Type: Application
    Filed: March 17, 2011
    Publication date: January 10, 2013
    Applicant: CORNELL UNIVERSITY (CCTEC)
    Inventors: Ronald G. Crystal, Bishnu De, Martin Hicks, Jonathan Rosenberg, Stephen M. Kaminsky